# ORGO catalysts: Organogenesis Holdings Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/orgo/catalysts

> Organogenesis Holdings Inc. (ORGO) has 1 upcoming catalyst. The next is the Organogenesis Holdings Inc. PDUFA date, April 24, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ORGO?

Organogenesis Holdings Inc. (ORGO) has 1 upcoming catalyst. The next is the Organogenesis Holdings Inc. PDUFA date, April 24, 2027. SEC Form 10-Q: "During June 2026, the FDA accepted the BLA for review and assigned a PDUFA target action date of April 24, 2027." [Calendar and source filings](https://sec-api.dev/companies/orgo/catalysts)

Source: SEC Form 10-Q, accession 0001193125-26-338049, https://www.sec.gov/Archives/edgar/data/1661181/000119312526338049/orgo-20260630.htm (retrieved 2026-11-12). Last confirmed 2026-08-06. Cite: https://sec-api.dev/companies/orgo/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Organogenesis Holdings Inc. |
| Ticker | ORGO (Nasdaq) |
| SEC CIK | 1661181 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/orgo |

## Cash runway

Cash $21.3M as of 2026-09-30; quarterly burn $18.6M; about 3.4 months of runway at that rate (XBRL company facts, accession 0001193125-26-449888).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2024 | [Organogenesis Holdings Inc. topline data readout](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed, met | "In May 2024, we announced that our Phase 3 RCT evaluating the safety and efficacy of ReNu, a cryopreserved ASA for the management of symptoms associated with knee OA, achieved its primary endpoint upon the analysis of positive top line data." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1661181/000119312526076730/orgo-20251231.htm)) |
| November 12, 2024 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000095017024125331/orgo-ex99_1.htm)) |
| February 27, 2025 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000095017025029021/orgo-ex99_1.htm)) |
| May 8, 2025 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000095017025066930/orgo-ex99_1.htm)) |
| August 5, 2025 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000095017025105032/orgo-ex99_1.htm)) |
| August 15, 2025 | [Amniotic suspension allograft primary completion](https://sec-api.dev/pdufa/amniotic-suspension-allograft) | ORGO | Knee Osteoarthritis | completed | "NCT06000410 (A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-15 (ACTUAL); Lead Sponsor Organogenesis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06000410)) |
| Sep 2025 | [Organogenesis Holdings Inc. topline data readout](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | scheduled | "We expect to have all patients completing the study by the end of the second quarter of 2025, and to complete the initial statistical analysis and have top-line data results from the second phase 3 study to share publicly in September 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1661181/000095017025029137/orgo-20241231.htm)) |
| November 6, 2025 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000119312525269654/orgo-ex99_1.htm)) |
| February 26, 2026 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000119312526076595/orgo-ex99_1.htm)) |
| May 7, 2026 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000166118126000007/orgo-ex99_1.htm)) |
| August 6, 2026 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000119312526338022/orgo-ex99_1.htm)) |
| November 5, 2026 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000119312526449831/orgo-ex99_1.htm)) |
| April 24, 2027 | [Organogenesis Holdings Inc. PDUFA date](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | scheduled | "During June 2026, the FDA accepted the BLA for review and assigned a PDUFA target action date of April 24, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1661181/000119312526338049/orgo-20260630.htm)) |

## Drugs

- [Amniotic suspension allograft](https://sec-api.dev/pdufa/amniotic-suspension-allograft): Knee Osteoarthritis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/orgo/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ORGO catalysts: Organogenesis Holdings Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/orgo/catalysts

```bibtex
@misc{secapidev_companies_orgo_catalysts_20261116,
  title        = {ORGO catalysts: Organogenesis Holdings Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/orgo/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_orgo_catalysts_20261116","title":"ORGO catalysts: Organogenesis Holdings Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/orgo/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
